1801-1820 of 1961 < first | | | last >
  • Career Advice: Seven Deadly Sins

    If you're not sure what a team is or what it can accomplish, you need to know the seven deadly sins that can destroy your team before it even gets to the huddle.

    JoAnn Hines, Chief People Packager
  • Therapeutic Dose: The Relief Tsunami

    Job security concerns failed to prevent pharmaceutical professionals and their employers from donating generously to regions devastated by December's tsunami.

    Paul Thomas, Managing Editor
  • Selecting an Automation Security Consultant

    This article by Charles Landis notes that you may want to consider hiring an expert to design a process control security program that is in your best interest financially and operationally.

  • Security: A Four-Step Approach

    There is no "silver bullet" for protecting the pharmaceutical supply chain. In this article, Susanne Hasselman, director of Axess Technologies, outlines a four-step strategy to improve brand protection.

  • Why Pharma's Anti-Tampering Strategies Don't Work

    "We've never seen what we would consider effective tamper-detection for a drug product," says Dr. Roger Johnston, head of the Vulnerability Assessment Team as Los Alamos National Laboratories. In this exclusive interview, Johnston gives us the ten top failings of anti-tampering efforts, and solutions for improvement. Also, click the "Download Now" button at the end of the article to obtain Johnston's PowerPoint presentation on improving tamper detection systems.

  • RFID Integration: Trying to Connect

    Middleware offers a way to integrate RFID, and the copious data it generates, with pharmaceutical manufacturers' current processes and systems.

    Doug Bartholomew, Contributing Editor
  • Chiron's Curse

    Its U.K. vaccine plant has been a nightmare. Could better risk management, due diligence, regulatory oversight or new technology have led to a different outcome?

  • PAT: The Value of Better Control

    Model Predictive Control (MPC) and better sensor technologies will allow pharmaceutical companies to better control their processes. Pavilion Technologies’ Eric Unrau and Michael Tay discuss the challenges and benefits of implementing MPC for pharmaceutical processes.

  • Use In-House Techniques to Minimize Implementation Costs

    Before investing in new instrumentation, be sure that you already have what you need to gain the process knowledge that PAT requires. Richard Poska, director of global pharmaceutical regulatory affairs for Abbott Labs’ CMC, GPRD Support, Small Molecules, shares his insights.

  • BMS Aims High Through Benchmarking

    Bristol-Myers Squibb benchmarked against the leanest, most agile consumer goods companies to transform its supply chain management processes and culture.

  • A Process Capability Roadmap

    The unexamined process cannot be improved, and process capability analysis offers new insights. Quality systems specialist Scott Tarpley, a consultant with Light Pharma, outlines the steps involved and prerequisites.

  • Whistleblower in Wyeth Case Speaks Out

    GMPs and financial disclosure are two sides of the same coin, claims Mark Livingston, plaintiff in a much-publicized whistleblower lawsuit against Wyeth Pharmaceuticals, in this exclusive reprint of a recent speech.

1801-1820 of 1961 < first | | | last >